Question 1

What is the approved dose of PT-141?

Accepted Answer

One version of PT-141 (bremelanotide) carries an approved label, and that label carries a number. A 2022 report of the Phase 3 work says patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. The amount, the route and the timing all sit in that one line. A 2020 review fills in the rest. It describes a shot under the skin that can be administered as needed approximately 45 minutes prior to sexual activity. The approval behind it is narrow, and it was granted for one named condition in one group of people: approved by the U.S. Food and Drug Administration for treatment of acquired generalized HSDD in premenopausal women. HSDD means low sexual desire that causes distress. We report that figure for the same reason we report that a compound is not approved for anything at all. It says what a regulator decided. It does not say what we think anyone ought to do.

Question 2

How much PT-141 should I take?

Accepted Answer

We do not answer that, and the reason is specific rather than legal cover. The approved figure belongs to one injection, prescribed for one diagnosis, in one group of people. Outside those three conditions nothing has been set for anybody. What can be reported is what the trials gave. A 2016 dose-finding trial randomised patients to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks, and its efficacy data covered 327 women. The Phase 3 work then ran the top of that range on its own, across 1202 patients in the pooled analysis. Those are trial arms and a regulator's decision, not advice from us. The gap between them and a vial bought outside a pharmacy is the subject of a section further down, and it is the whole difficulty with this compound.

Question 3

Is there a PT-141 dosage chart?

Accepted Answer

Charts circulate showing a ladder of amounts with weeks printed beside them, presented as though one sequence applied to everybody. The published record supports something considerably shorter: a single approved figure of 1.75 mg, and one dose-finding trial beneath it at 0.75, 1.25 or 1.75 mg. There is no titration anywhere in that. Nobody escalated anybody through those dose-finding amounts, because they were parallel arms, assigned at random and compared against placebo. A chart that reads as a climb is describing a structure the trials never possessed. One historical source deserves particular caution. A 2008 fixed dose, randomized study of bremelanotide in female subjects with arousal disorder has been retracted at the request of the Editor-in-Chief. Any figure traced back to that paper is traced back to a withdrawn one, which is different from being traced back to a weak one.

Question 4

What amounts were tested in the PT-141 trials?

Accepted Answer

Three amounts appear in the dose-finding work, and one of them carried through to approval. Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks gave the comparison. For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month. The work around those trials was large. A 2022 safety review records that the clinical development program comprised 3500 subjects in 43 completed studies, and that in the phase 3 studies, subjects took bremelanotide for up to 18 months. The trial registry shows the same shape. Two completed Phase 3 entries test the same compound in premenopausal women with low sexual desire, and the Phase 2 work before them sat in that group too. Nothing on the registry tests a second amount, because by that stage the amount had been chosen.

Question 5

What is the PT-141 dosage for women?

Accepted Answer

This is the one group the record really covers, and for them the answer is the approved one: 1.75 mg, taken as needed, from an autoinjector that delivers it underneath the skin. In the two Phase 3 trials participants administered it before sexual activity, for 24 weeks, and the pooled analysis covered 1202 patients. Nothing else on this page rests on comparable evidence. The approval is narrower than the word women suggests. It was granted for acquired generalized HSDD in premenopausal women, which leaves women past the menopause outside it. A later Phase 3 bridging trial, registered and listed as completed, enrolled that identical population again. Two reviews weigh how much that accumulated evidence is worth. A 2025 look at cancer-survivorship guidance notes that advice covering bremelanotide for low sex drive rests on limited data. A 2017 review says trials in this field have significant design, dosing or generalizability limitations. Both are evaluating the trials rather than the participants inside them.

Question 6

What is the PT-141 dosage for men?

Accepted Answer

No amount has been established for men, and the reason is that none of the registered trials behind the approval enrolled one. Every completed entry on the registry names premenopausal women or female subjects in its own title, from a Phase 2 study to Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) through to the Phase 3 bridging trial. So anything circulating as a male figure has been carried across from a female population by somebody, and no published work has made or examined that step. We do not make it either. The absence runs in a particular direction worth naming. It is not a finding that the approved amount is wrong for men; the question has not been asked in print. The one registered entry outside female sexual function studied Bremelanotide in Diabetic Kidney Disease, which measures something different again.

Question 7

How often can PT-141 be taken?

Accepted Answer

The label sets two ceilings and a stopping rule, and they are the clearest numbers on this page. A 2020 review records that prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month. The same review adds that individuals should discontinue use after 8 weeks without benefit, which is a stopping rule rather than a schedule. Timing sits alongside frequency. That review describes a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity, which is an on-demand pattern rather than a daily one. Those ceilings were not chosen arbitrarily. A 2022 safety review reports that focal hyperpigmentation, meaning darkened patches of skin, was rare when bremelanotide was dosed in accordance with label recommendations. What happens on other schedules is set out on our safety page.

Question 8

What is a 10 mg PT-141 dosage?

Accepted Answer

Ten milligrams is a vial size rather than an amount anybody has administered. The approved figure is 1.75 mg, and the largest assignment in the dose-finding trial was also 1.75 mg, so a 10 mg vial holds several times the approved amount in total. The arithmetic underneath that is straightforward and worth stating. A 10 mg vial contains 10,000 micrograms of powder before anything is added to it, and the approved amount is 1,750 micrograms, so the proportion between them is fixed whatever volume of diluent goes in afterwards. What the proportion cannot do is transfer the label. The approved figure was established in trials using a pharmacy injection of known identity and known strength, prescribed for one diagnosis. A vial of powder with 10 mg printed on it has no label, and nothing about the approved amount has been shown to apply to its contents.

Question 9

Does the approved schedule apply to research-grade PT-141?

Accepted Answer

No, and this distinction governs every figure above it. The record on this page belongs to one approved injection: patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity, under a label that permits no more than 1 dose in 24 hours and no more than 8 doses per month. Three things arrive with an approval and do not travel. The amount is the first, because it was established in trials that knew precisely what was in the syringe. The schedule is the second, because those ceilings were set against that same injection. The identity and strength of the material is the third, and it is the thing a label actually guarantees. A vial sold as research-grade PT-141 carries none of those. It has no label, no regulator standing behind its contents and no established amount, so nothing on this page has been shown to apply to what is inside it.

Question 10

How much BAC water do you put in PT-141?

Accepted Answer

Reconstitution is arithmetic, and the arithmetic does not depend on anybody's protocol. A 10 mg vial contains 10,000 micrograms of powder, so 1 mL of bacteriostatic water leaves the concentration at 10,000 micrograms per mL, 2 mL leaves it at 5,000 micrograms per mL, and 5 mL leaves it at 2,000 micrograms per mL. The diluent volume establishes concentration and alters nothing else. It does not change how much compound is sitting in the glass, and it cannot settle the second half of the calculation, which is the amount anybody would eventually draw. For the approved injection that second half never arises, because the amount is fixed by a label and delivered by an autoinjector rather than drawn out of a vial. For an unlabelled vial it is not fixed by anything at all, so the arithmetic stops at a concentration rather than continuing into a volume on a syringe.

Question 11

Is there a PT-141 nasal spray dose?

Accepted Answer

No nasal preparation has been approved and no trial among the research behind this page reports an amount for one. What reached approval is an injection under the skin, delivered by an autoinjector at 1.75 mg, which is where the whole published record sits. Route is not a detail that can be swapped out. A 2025 delivery experiment measured the size of that question directly: a patch held against the cheek lining of beagle dogs achieved a relative bioavailability of 26% for bremelanotide, meaning roughly a quarter as much reached the bloodstream as from an injection under the skin. That measurement came from dogs and from a patch rather than a spray, so it does not transfer either. What it does establish is the scale of the problem. Changing how a peptide gets in changes how much of it arrives, and for a nasal PT-141 no study among the research behind this page has published that number at all.

Question 12

How much does PT-141 cost?

Accepted Answer

No source among the research behind this page reports a price, for the approved injection or for anything else, and a price is not the sort of thing research literature records. What the literature does establish is which version has a regulated supply behind it and which version does not. The approved injection was cleared by the U.S. Food and Drug Administration for treatment of acquired generalized HSDD in premenopausal women, and it is dispensed on prescription for that diagnosis. Everything else sits outside the approval, including nasal preparations, for which no approved article exists and therefore no approved price. Figures quoted elsewhere come from sellers rather than from any published record, and we have no mechanism for checking them. What a price buys is the part worth considering: for the approved injection it buys material of known identity at a known strength, and for an unlabelled vial no analysis among the research behind this page has measured either.

Question 13

Why do the published amounts vary?

Accepted Answer

Only two sets of figures really exist, and they differ for a simple reason. One set comes from a dose-finding trial, which was there to compare 0.75, 1.25 and 1.75 mg against placebo and against each other. The other is the single amount that comparison picked, carried into two matched Phase 3 studies with an optional 52-week open-label extension. A third set circulates in older summaries, and it comes from work that no longer stands. A 2008 fixed-dose study in women was withdrawn after expert reviewers raised multiple concerning questions about the methodology, results, and statistical interpretation as presented in this article. Beyond those, the reviews that mention this compound are careful about what they report. One calls the data behind the advice limited, and a 2017 review says trials have significant design, dosing or generalizability limitations. Neither is describing a settled range of amounts.

Study	Amounts assigned	Analysed
2016 dose-finding trial	Placebo, 0.75, 1.25 or 1.75 mg under the skin, as desired, over 12 weeks	327 women
Phase 3 work, pooled	1.75 mg, the top of that range	1202 patients

PT-141 protocols in the published literature